MorningLyte: Study of Mosunetuzumab Plus Lenalidomide Compared to Anti-CD20 Anti-body + Chemotherapy in Follicular Lymphoma FLIPI2-5 (clinicaltrials.gov) - Sep 26, 2026 - P3 | N=790 | Active, not recruiting | Sponsor: The Lymphoma Academic Research Organisation | Recruiting ➔ Active, not recruiting
Enrollment closed • Follicular Lymphoma • Hematological Malignancies • Lymphoma • Oncology • CD20
|